Cargando…

Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost

Detalles Bibliográficos
Autores principales:	Costa, Enrico, Tibalinda, Prosper, Sterzi, Enrico, Leufkens, Hubert M. G., Makani, Julie, Kaale, Eliangiringa, Luzzatto, Lucio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756644/ https://www.ncbi.nlm.nih.gov/pubmed/32974896 http://dx.doi.org/10.1002/ajh.26007

Ejemplares similares

Pharmaceuticals imports in Tanzania: Overview of private sector market size, share, growth and projected trends to 2021
por: Wande, Dickson Pius, et al.
Publicado: (2019)

Formulation development of chewable albendazole tablets with improved dissolution rate
por: Kimaro, Emmanuel, et al.
Publicado: (2019)

Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework
por: Mori, Amani Thomas, et al.
Publicado: (2012)

Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design
por: Tibalinda, Prosper, et al.
Publicado: (2016)

Make Haste Slowly
Publicado: (1874)

Make Haste Slowly
Publicado: (1870)

Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine
por: Kilonzi, Manase, et al.
Publicado: (2022)

The Role of Evidence in the Decision-Making Process of Selecting Essential Medicines in Developing Countries: The Case of Tanzania
por: Mori, Amani Thomas, et al.
Publicado: (2014)

Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania
por: Makubi, Abel, et al.
Publicado: (2016)

Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators
por: Mlyuka, Hamu J., et al.
Publicado: (2022)

Reforms: a quest for efficiency or an opportunity for vested interests’? a case study of pharmaceutical policy reforms in Tanzania
por: Mori, Amani Thomas, et al.
Publicado: (2013)

The prevalence of human immunodeficiency and of hepatitis B viral infections is not increased in patients with sickle cell disease in Tanzania
por: Shayo, Grace, et al.
Publicado: (2021)

Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western Tanzania
por: Ambrose, Emmanuela E, et al.
Publicado: (2023)

Limited Exchange Transfusion Can Be Very Beneficial in Sickle Cell Anemia with Acute Chest Syndrome: A Case Report from Tanzania
por: Chamba, Clara, et al.
Publicado: (2018)

Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority
por: Mori, Amani Thomas, et al.
Publicado: (2018)

Sickle cell disease, malaria and dengue fever: a case of triple jeopardy
por: Iversen, Per O, et al.
Publicado: (2019)

Sickle Cell Anaemia and Malaria
por: Luzzatto, Lucio
Publicado: (2012)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Haste and Health
por: Preston, S. H.
Publicado: (1889)

Emerging Antimicrobial Drug Resistance in Africa and Latin America: Search for Reasons
por: Hoellein, Ludwig, et al.
Publicado: (2022)

Modeling solutions to Tanzania's physician workforce challenge
por: Goodell, Alex J., et al.
Publicado: (2016)

Sterile ‘Abscess’ of the Spleen and the Sickle Cell Trait
por: Luzzatto, Lucio
Publicado: (2018)

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision
por: Creary, Susan, et al.
Publicado: (2015)

Sickle cell disease and malaria: decreased exposure and asplenia can modulate the risk from Plasmodium falciparum
por: Mwaiswelo, Richard O., et al.
Publicado: (2020)

A ten year review of the sickle cell program in Muhimbili National Hospital, Tanzania
por: Makani, Julie, et al.
Publicado: (2018)

Hastings—Malvern—Leamington
Publicado: (1829)

"In Hot Haste," etc.
Publicado: (1888)

Continuous Cultures of Plasmodium Falciparum Established in Tanzania from Patients with Acute Malaria
por: Urio, Florence, et al.
Publicado: (2021)

The Quality of Selected Essential Medicines Sold in Accredited Drug Dispensing Outlets and Pharmacies in Tanzania
por: Kaale, Eliangiringa, et al.
Publicado: (2016)

Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet
por: Luzzatto, Lucio, et al.
Publicado: (2022)

Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation
por: Heim, Beatrice, et al.
Publicado: (2017)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

On directional Metropolis Hastings algorithms
por: Eidsvik, J, et al.
Publicado: (2003)

Robert William Hastings Jarvie
Publicado: (1943)

Stability of noisy Metropolis–Hastings
por: Medina-Aguayo, F. J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sh0ebrv8np402tf3mbernc1tvu